Lincoln Pharmaceuticals Limited share price

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, anti-infective, anti-bacterial, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics in the form of tablets, capsules, injectables, dry syrups, sprays, ointments etc. It exports its products to Europe, Canada, Latin and North America, Africa, Asia, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is bas…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: LINCOLNISIN INE405C01035

16 Oct 2026, 3:30 PM IST₹545.60▼ 9.40 (1.69%)

Market Cap₹ 1,093 Cr.
Current Price₹ 545.60
High / Low₹ 770 / 440
Stock P/E11.3
Book Value₹ 378
Dividend Yield0.32 %
ROCE14.9 %
ROE12.30 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 48.16
Price / Book1.44
OPM13.0 %
Debt / Equity0.01
Sales growth (5Y)13.2 %
Profit growth (5Y)20.5 %
Promoter holding55.1 %
EV / EBITDA8.4
Beta0.47
All-time high₹ 980

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
LINCOLN	-7.64%	-9.33%	-7.60%	+12.74%	+3.92%	+3.78%	+7.73%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Lincoln Pharmaceuticals Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,093 crore.
It trades at 11.3 times its last 12 months' earnings and 1.4 times book value.
Revenue grew 13.2% a year over the last 5 years, profit 20.5% a year.
Return on equity was 12.3% and return on capital employed 14.9% in the latest year.
Debt was 0.01 times shareholders' equity.
The share price is 29.1% below its 52-week high and up 3.9% over one year.
Promoters and insiders hold about 55.1%; institutions about 0.8%.

Pros

Company is almost debt-free (debt is 0.01 times equity).
Profit has grown 20.5% a year over the last 5 years.
Latest quarter (Jun 2026): sales up 15% and profit up 31% from a year ago.
Healthy return on equity of 14.1% on average over the last 3 years.
Trades at 11.3 times earnings, below its 3-year median of 13.8.

Cons

Other income makes up 33% of profit before tax.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Lincoln Pharmaceuticals Limited

Employees: 1,352
Head office: Ahmedabad

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Lincoln Pharmaceuticals	545.60	11.3	1,093	0.32	36	30.93	177	15.07	14.9	12.3	1.44	13.0	0.01	55.06	671	13.2
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 46 Co.	1,712.85	31.8	17,754	0.34	679	22.61	5,999	18.81	14.9	14.4	4.27	16.4	0.21	54.93	20,499	13.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	136	156	146	142	147	161	147	168	154	163	166	187	177
YOY Sales Growth %	9.84%	10.93%	9.48%	26.71%	8.60%	3.35%	0.07%	18.03%	4.61%	1.33%	13.49%	11.35%	15.07%
	115	125	117	124	125	133	123	141	130	138	143	162	150
Material Cost %	47%	47%	46%	52%	48%	45%	47%	48%	45%	47%	46%	48%	48%
Employee Cost %	20%	16%	18%	18%	20%	17%	19%	16%	21%	19%	18%	17%	19%
Other Expenses %	18%	17%	16%	18%	17%	20%	18%	20%	19%	19%	22%	22%	18%
Operating Profit	21	31	30	18	23	28	24	27	24	25	24	25	27
OPM %	15%	20%	20%	13%	15%	18%	16%	16%	15%	16%	14%	13%	15%
Other Income	8	9	11	7	10	10	9	-7	15	7	15	-4	24
Interest	0	0	0	0	0	0	1	0	0	0	0	0	0
Depreciation	3	3	3	3	3	3	3	3	3	4	4	4	4
Profit before tax	25	37	38	22	29	35	29	16	35	29	35	17	48
	25%	25%	26%	16%	20%	24%	28%	29%	22%	31%	18%	30%	24%
Current tax	6	9	7	4	6	5	8	7	4	8	6	9	5
Deferred tax	1	1	2	-0	0	3	-0	-2	4	0	0	-4	6
	19	28	28	19	24	26	21	12	28	20	29	12	36
YOY Profit Growth %	26.66%	16.62%	29.74%	48.04%	24.50%	-4.79%	-25.93%	-37.76%	16.91%	-24.10%	37.70%	0.51%	30.93%
EPS in Rs	9.49	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	136	156	146	142	147	161	147	168	154	163	166	187	177
YOY Sales Growth %	9.84%	10.93%	9.48%	26.71%	8.60%	3.35%	0.07%	18.03%	4.61%	1.33%	13.49%	11.35%	15.07%
	115	125	117	124	125	133	123	141	130	138	143	162	150
Material Cost %	47%	47%	46%	52%	48%	45%	47%	48%	45%	47%	46%	48%	48%
Employee Cost %	20%	16%	18%	18%	20%	17%	19%	16%	21%	19%	18%	17%	19%
Other Expenses %	18%	17%	16%	18%	17%	20%	18%	20%	19%	19%	22%	22%	18%
Operating Profit	21	31	30	18	23	28	24	27	24	25	24	25	27
OPM %	15%	20%	20%	13%	15%	18%	16%	16%	15%	16%	14%	13%	15%
Other Income	8	9	11	7	10	10	9	-7	15	7	15	-4	24
Interest	0	0	0	0	0	0	1	0	0	0	0	0	0
Depreciation	3	3	3	3	3	3	3	3	3	4	4	4	4
Profit before tax	25	37	38	22	29	35	29	16	35	29	35	17	48
	25%	25%	26%	16%	20%	24%	28%	29%	22%	31%	18%	30%	24%
Current tax	6	9	7	4	6	5	8	7	4	9	6	9	5
Deferred tax	1	1	2	-0	0	3	-0	-2	4	-0	0	-4	6
	19	28	28	19	24	26	21	12	28	20	29	12	36
YOY Profit Growth %	26.66%	16.62%	29.74%	48.05%	24.50%	-4.79%	-25.93%	-37.76%	16.91%	-24.10%	37.70%	0.51%	30.93%
EPS in Rs	9.49	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	362	362	510	581	623	671	694
YOY Sales Growth %			41.11%	13.76%	7.35%	7.67%
	309	309	421	481	522	573	593
Material Cost %	53%	53%	47%	48%	47%	46%	47%
Employee Cost %	14%	14%	18%	18%	18%	19%	18%
Other Expenses %	18%	18%	17%	17%	19%	20%	20%
Operating Profit	52	52	89	100	101	98	101
OPM %	14%	14%	17%	17%	16%	15%	15%
Other Income	5	5	22	34	22	33	42
Interest	5	5	2	1	2	1	1
Depreciation	6	6	9	11	13	14	15
Profit before tax	46	46	100	122	109	116	128
	25%	25%	27%	24%	25%	24%	25%
Current tax	10	10	26	25	25	28
Deferred tax	1	1	2	3	2	-0
	35	35	73	93	82	88	96
Minority share	0	0
Profit to shareholders	35	35
YOY Profit Growth %			110.39%	27.99%	-11.74%	6.74%
EPS in Rs	17.32	17.32	36.40	46.58	41.11	43.88	48.16

Compounded Sales Growth

5 Years:: 13%
3 Years:: 10%
TTM:: 10%

Compounded Profit Growth

5 Years:: 20%
3 Years:: 6%
TTM:: 12%

Stock Price CAGR

5 Years:: 8%
3 Years:: 4%
1 Year:: 4%

Return on Equity

4 Years:: 14%
Last Year:: 12%

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	326	326	376	413	472	510	581	623	671	694
YOY Sales Growth %			15.54%	9.83%	14.29%	8.10%	13.76%	7.35%	7.67%
	280	280	317	332	377	421	481	522	573	593
Material Cost %	53%	53%	50%	49%	46%	47%	48%	47%	46%	47%
Employee Cost %	15%	15%	15%	14%	15%	18%	18%	18%	19%	18%
Other Expenses %	19%	19%	20%	18%	19%	17%	17%	19%	20%	20%
Operating Profit	46	46	59	81	95	89	100	101	98	101
OPM %	14%	14%	16%	20%	20%	17%	17%	16%	15%	15%
Other Income	6	6	12	7	10	22	34	22	33	42
Interest	4	4	2	1	1	2	1	2	1	1
Depreciation	4	4	5	6	8	9	11	13	14	15
Profit before tax	43	43	64	81	96	100	122	109	116	128
	24%	24%	23%	25%	28%	27%	24%	25%	24%	25%
Current tax	10	10	15	20	1	26	25	25	28
Deferred tax	1	1	-0	1	26	2	3	2	-0
	33	33	50	60	69	73	93	82	88	96
YOY Profit Growth %			51.31%	21.88%	14.81%	5.11%	27.99%	-11.74%	6.74%
EPS in Rs	16.38	16.38	24.78	30.20	34.63	36.40	46.58	41.11	43.88	48.16
Dividend Payout %						4%	3%	4%	4%

Compounded Sales Growth

5 Years:: 10%
3 Years:: 10%
TTM:: 10%

Compounded Profit Growth

5 Years:: 8%
3 Years:: 6%
TTM:: 12%

Stock Price CAGR

5 Years:: 8%
3 Years:: 4%
1 Year:: 4%

Return on Equity

4 Years:: 14%
Last Year:: 12%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	20	20	20	20
Reserves	482	573	652	738
	2	1		4
Short term borrowings	2	1		4
	83	106	125	128
Trade payables	51	72	85	85
Current liabilities	72	92	106	111
Total Liabilities	587	700	797	890
	158	187	186	198
Gross block	205	243	186	280
Accumulated depreciation	46	56	69	82
Goodwill & intangibles	0	0	0	1
CWIP	8	8	4	8
	421	506	607	685
Inventories	70	77	79	80
Trade receivables	136	162	166	161
Cash & equivalents	5	6	13	22
Current assets	367	438	500	583
Total Assets	587	700	797	890

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	39	63	93	106
Profit for the year	73	93	82	88
Working capital changes	-31	-16	9	10
Direct taxes paid	-30	-26	-26	-25
	-37	-57	-79	-98
Fixed assets purchased	-14	-40	-19	-26
Fixed assets sold	1	0	0	2
Investments purchased	-63	-100	-85	-69
Investments sold	74	75	56	36
	-5	-5	-6	0
Proceeds from borrowings	19	20	68	4
Repayment of borrowings	-20	-21	-69
Interest paid	-1	-1	-2	-1
Dividends paid	-3	-3	-4	-4
Net Cash Flow	-2	1	8	8
Free Cash Flow	25	24	74	80

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	14.5%	17.0%	13.0%	12.3%
ROCE	—	19.8%	20.3%	16.0%	14.9%
Operating margin	—	16.0%	15.4%	14.5%	13.0%
Net margin	—	14.4%	16.1%	13.4%	13.3%
Debt / equity	—	0.00	0.00	—	0.01
Current ratio	—	5.09	4.74	4.71	5.25
Debtor days	—	99	102	99	89
Inventory days	—	105	101	98	94
Days payable	—	76	94	106	99
Cash conversion cycle	—	128	109	91	84
Working capital days	—	213	217	234	260

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 49.78%
FIIs 4.60%
DIIs 0.27%
Public 45.36%

%	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	48.67%	50.53%	49.80%	49.53%	49.78%	49.78%	49.78%	49.78%	49.78%	49.78%	49.78%	49.78%
	1.74%	2.59%	3.23%	3.93%	3.95%	5.19%	5.16%	5.00%	4.72%	4.70%	5.19%	4.60%
Foreign portfolio investors (Cat. I)	1.03%	1.34%	1.73%	2.63%	2.59%	3.42%	3.41%	3.47%	3.35%	3.32%	3.80%	3.17%
Foreign portfolio investors (Cat. II)	0.71%	1.25%	1.49%	1.30%	1.36%	1.77%	1.75%	1.53%	1.38%	1.38%	1.40%	1.43%
			0.06%	0.05%	0.04%			0.01%	0.01%	0.01%	1.09%	0.27%
Alternative investment funds			0.06%	0.05%	0.04%				0.01%	0.01%	1.08%	0.27%
	49.58%	46.88%	46.91%	46.49%	46.24%	45.03%	45.06%	45.22%	45.49%	45.52%	43.94%	45.36%
Retail (up to ₹2 lakh)	27.31%	27.95%	27.98%	27.43%	26.47%	26.69%	27.78%	26.78%	25.90%	25.10%	23.58%	24.35%
HNIs (above ₹2 lakh)	10.01%	9.52%	9.80%	9.93%	10.63%	9.45%	8.93%	9.86%	10.36%	11.18%	11.12%	11.76%
NRIs	2.07%	2.10%	2.06%	2.04%	2.18%	2.11%	2.12%	2.08%	2.59%	2.59%	2.48%	2.47%
Bodies corporate	4.29%	1.94%	1.76%	1.78%	1.70%	1.68%	1.25%	1.26%	1.31%	1.35%	1.08%	0.99%
IEPF	0.21%	0.21%	0.26%	0.26%	0.26%	0.26%	0.28%	0.28%	0.28%	0.31%	0.30%	0.30%
No. of Shareholders	27,480	28,670	29,316	31,375	29,967	31,330	31,848	31,867	32,370	31,026	28,303	29,396

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 11 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

No recent coverage found.

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Lincoln Pharmaceuticals Limited

What is the share price of Lincoln Pharmaceuticals Limited today?

Lincoln Pharmaceuticals Limited (LINCOLN) last traded at ₹545.60 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Lincoln Pharmaceuticals Limited?

About ₹1,093 crore at the latest price.

What is the P/E ratio of Lincoln Pharmaceuticals Limited?

About 11.3 times its earnings over the last 12 months.

Is Lincoln Pharmaceuticals Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Lincoln Pharmaceuticals Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Lincoln Pharmaceuticals Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Lincoln Pharmaceuticals Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Lincoln Pharmaceuticals Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next